SUDOSCAN, an Innovative, Simple and Non-Invasive Medical Device for Assessing Sudomotor Function

Sensors (Basel). 2022 Oct 6;22(19):7571. doi: 10.3390/s22197571.

Abstract

Diabetic autonomic neuropathy is probably the most undiagnosed but serious complication of diabetes. The main objectives were to assess the prevalence of peripheral and autonomic neuropathy in a population of diabetic patients, analyze it in a real-life outpatient unit scenario and determine the feasibility of performing SUDOSCAN tests together with widely used tests for neuropathy. A total of 33 patients were included in the study. Different scoring systems (the Toronto Clinical Neuropathy Score-TCNS; the Neuropathy Disability Score-NDS; and the Neuropathy Symptom Score-NSS) were applied to record diabetic neuropathy (DN), while the SUDOSCAN medical device was used to assess sudomotor function, detect diabetic autonomic neuropathy and screen for cardiac autonomic neuropathy (CAN). Fifteen (45.5%) patients had sudomotor dysfunction. The SUDOSCAN CAN risk score was positively correlated with the hands' electrochemical sweat conductance (ESC), diastolic blood pressure (DBP), the level of the glycated hemoglobin, as well as with the TCNS, NDS and NSS. Performing SUDOSCAN tests together with other tests for DN proved to be a feasible approach that could be used in daily clinical practice in order to screen for DN, as well as for the early screening of CAN, before more complex and time-consuming tests.

Keywords: SUDOSCAN; cardiac autonomic neuropathy; diabetes mellitus; medical device; sudomotor function.

MeSH terms

  • Autonomic Nervous System
  • Diabetic Neuropathies* / diagnosis
  • Galvanic Skin Response
  • Glycated Hemoglobin
  • Humans

Substances

  • Glycated Hemoglobin